In a press release distributed on September 8, 2002, Revance Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has approved DAXXIFY™ – a BOTOX® and Dysport® rival – for injection for the temporary improvement of moderate to severe frown lines in adults.
But this then begs the question …
What Is DAXXIFY™?
According to Revance, “DAXXIFY™ is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum albumin and animal-based components, and addresses the duration of treatment effect.”
In layman’s terms? After years researching an effective neuromuscular blocking agent that could be administered without a needle, Revance found a way to keep the formula stable with peptides instead of the animal protein or human serum that is typically used.
This FDA approval is Revance’s first and expands its share of the growing $3.2 billion facial injectables market in the U.S. with the introduction of its longer-lasting BOTOX® rival.
How Is DAXXIFY™ Different from BOTOX®?
Revance asserts that DAXXIFY™ is the first facial injectable to see results lasting up to 6 months to prevent and manage wrinkles, half of BOTOX®’s near-quarterly maintenance.
“The FDA approval of DAXXIFY™ is a foundational achievement for the company as it marks the culmination of years of pioneering research and development made possible by the outstanding execution of our talented team, along with strong support from the medical and investor communities,” said Mark J. Foley, Chief Executive Officer, in the release.
The reported results of a 2,700-participant clinical trial with approximately 4,200 treatments include:
- Results in as early as one day after treatment, though more typically seen within two.
- 98% of people showed no signs of wrinkle development at 4-week follow-up post-treatment
- 88% of people showed clinically significant wrinkle improvement at a 4-week follow-up
When Will DAXXIFY™ Be Available To The Public?
Set to launch in 2020 but delayed due to the pandemic, those eager to try DAXXIFY™ may have to wait just a bit longer as the Revance has yet to reveal a price and will utilize only a preview strategy for two quarters.
“We want to get this in the hands of a small group of physicians that can use this product to understand how to get the best results,” Foley said in an interview. “We wanted to give that small group of injectors an opportunity to play with it before we went to the broad commercial launch.”
